The RaniPill capsule, developed by Rani Therapeutics, is a novel technology that replaces the need for injections by delivering a precise therapeutic dose of medication to the intestinal wall. This platform has the potential to transform medicine and improve outcomes for millions of patients who currently rely on chronic self-injections. Rani Therapeutics has successfully conducted preclinical and clinical studies to evaluate safety and bioavailability using the RaniPill capsule, and their extensive intellectual property portfolio provides a competitive advantage in the market. The company has raised significant funding from investors such as Google Ventures, Novartis, and AstraZeneca to support the development and commercialization of their innovative oral drug delivery technology.